View Financial HealthDT Cloud Star Acquisition 配当と自社株買い配当金 基準チェック /06DT Cloud Star Acquisition配当金を支払った記録がありません。主要情報n/a配当利回り133.8%バイバック利回り総株主利回り133.8%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updates新しいナラティブ • Jun 18A SPAC in the Endgame Between Lifeboat and Siren SongThe Metaphor Upfront: Investing in DTSQ is like buying a ticket on a lifeboat whose captain has just decided to purchase a luxuriously labeled but barely inspected cargo ship in the middle of the open sea. Those who disembark in time get their money back plus a small interest premium.お知らせ • Apr 12DT Cloud Star Acquisition Corp Receives Notice of Non-Compliance with Nasdaq Listing Rule 5450(a)(2)On April 6, 2026, DT Cloud Star Acquisition Corporation (the Company) received a letter (the Deficiency Letter) from the Listing Qualifications Staff of The Nasdaq Stock Market (Nasdaq) indicating that based on a shareholder range analysis provided by the Company to Nasdaq dated March 27, 2026, the Company is not in compliance with Listing Rule 5450(a)(2) (the Minimum Public Holders Rule), which requires the Company to maintain at least 400 total holders for continued listing on The Nasdaq Global Market. The Deficiency Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market. The Deficiency Letter states that the Company has 45 calendar days, or until May 21, 2026, to submit a plan to regain compliance with Listing Rule 5450(a)(2). If Nasdaq accepts the Company's plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Deficiency Letter to evidence compliance with Listing Rule 5450(a)(2). If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the Capital Market). The Company is exploring all options to regain compliance with Listing Rule 5450(a)(2) and intends to submit a plan to regain compliance within the required timeframe. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.お知らせ • Feb 05Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction.Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction on February 2, 2026. A cash consideration of $1.5 billion will be paid by Primegen Us, Inc. As part of consideration, $1.5 billion is paid towards common equity of DT Cloud Star Acquisition Corporation. The combined company is expected to operate as PrimeGen US. PrimeGen US is anticipated to list on the Nasdaq, subject to Nasdaq approval, under a new ticker symbol. The transaction is subject to subject to antitrust regulations, minimum balance sheet requirements, approval by regulatory board, approval of offer by acquirer shareholders and approval of offer by target shareholders. The transaction is currently expected to close in the second half of 2026. A.G.P. / Alliance Global Partners, LLC acted as financial advisor for Primegen Us, Inc. Sichenzia Ross Ference Carmel LLP acted as legal advisor for Primegen Us, Inc. Loeb & Loeb LLP acted as legal advisor for DT Cloud Star Acquisition Corporation. Steven C. Schinko of Schinko Law acted as legal advisor for Primegen Us, Inc.お知らせ • Jan 23DT Cloud Star Acquisition Corporation Receives A Deficiency Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn January 15, 2026, DT Cloud Star Acquisition Corporation received a letter (the “Deficiency Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on its Market Value of Listed Securities (“MVLS”) for the period from November 21, 2025 to January 6, 2026, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(b)(2)(A), to maintain a minimum MVLS of $50,0000,000. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until July 14, 2026, in which to regain compliance with Nasdaq continued listing requirement. Nasdaq will provide written confirmation of compliance to the Company and close this matter if the Company’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days during this compliance period. In the event the Company does not regain compliance prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting, in which situation the Company may appeal the delisting determination to a Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the “Capital Market”). The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(b)(2)(A), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.お知らせ • Nov 29DT Cloud Star Acquisition Corporation Appoints Xunyong Zhou as DirectorOn November 26, 2025, the board of directors of DT Cloud Star Acquisition Corporation (the “Company”) appointed Dr. Xunyong Zhou as a director of the Company. Dr. Zhou, aged 50, is an entrepreneur and researcher with over 6 years of experience in biotechnology and health innovation. Dr. Zhou’s main topic of research is enzyme-based theory for food products, cosmetics, daily chemicals and tea, and he holds over 20 patents as of now. Dr. Zhou is a pioneering figure in biotechnology and digital health innovation. He has served as director for Huakang Biomedical Holdings Company Limited since November 2025. Since January 2023, He has been leading advancements in biological enzyme solutions and cell therapy technologies through Nanjing Hezhen Holding Group Co. Ltd., where he serves as chairman and integrates healthcare generative pre-training transformer and enzyme therapy expertise to co-create a collaborative platform offering next-generation health solutions. Dr. Zhou also oversees Changsha Kerong Health Technology Co. Ltd., which has built a multidisciplinary health service team comprising medical, product, and service experts centered on delivering AI-enhanced health education, health consultation, and health management services. From March 2019 to January 2023, Dr. Zhou took the role of chairman for Zhenzhen Suqian Biotechnology Co. Ltd. Dr. Zhou graduated from Tianjin University of the PRC with a bachelor degree of engineering majoring in business administration in 2002 and Fudan University of the PRC with a master degree of laws in 2011. Dr. Zhou subsequently obtained his doctorate degree in business administration from the Université Nice Sophia Antipolis in Nice, France in 2016. He is currently the honorary chairman of the Vaccine and Immune Health Branch of the Liaoning Immunology Society and a member of the National Enzyme Engineering and Fermentation Engineering Professional Committee.お知らせ • Sep 12DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025, at 10:00 China Standard Time. Location: offices of loeb & loeb llp, 2206-19, 1 connaught pl, central, Hong Kongお知らせ • Apr 16Dt Cloud Star Acquisition Corporation Announces Chief Executive Officer Changes, Effective April 14, 2025DT Cloud Star Acquisition Corporation announced that effective April 14, 2025, Bian Fan was removed as Chief Executive Officer of DT Cloud Star Acquisition Corporation by the written consent of the board of directors of the Company. On the same date, to fill the vacancy, the Board appointed Sam Zheng Sun as the Chief Executive Officer of the Company. Mr. Sun was a managing director of the private equity investment department of Affinity Equity Partners, a Hong Kong-headquartered firm that focuses on private equity investments across South Korea, Australia and New Zealand, Greater China and Southeast Asia between March 2021 and February 2023. Prior to that, Mr. Sun was a partner at Sequoia Capital based in Beijing, where he focused on private equity investments, between October 2018 and April 2020. Mr. Sun obtained his MBA degree from UCLA Anderson School of Management in 2007 and Bachelor’s degree in computer science and economics from University of Pittsburgh in 1997.決済の安定と成長配当データの取得安定した配当: DTSQの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: DTSQの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場DT Cloud Star Acquisition 配当利回り対市場DTSQ 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (DTSQ)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Capital Markets)2.0%アナリスト予想 (DTSQ) (最長3年)n/a注目すべき配当: DTSQは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: DTSQは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: DTSQの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: DTSQが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/18 23:23終値2026/06/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DT Cloud Star Acquisition Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
新しいナラティブ • Jun 18A SPAC in the Endgame Between Lifeboat and Siren SongThe Metaphor Upfront: Investing in DTSQ is like buying a ticket on a lifeboat whose captain has just decided to purchase a luxuriously labeled but barely inspected cargo ship in the middle of the open sea. Those who disembark in time get their money back plus a small interest premium.
お知らせ • Apr 12DT Cloud Star Acquisition Corp Receives Notice of Non-Compliance with Nasdaq Listing Rule 5450(a)(2)On April 6, 2026, DT Cloud Star Acquisition Corporation (the Company) received a letter (the Deficiency Letter) from the Listing Qualifications Staff of The Nasdaq Stock Market (Nasdaq) indicating that based on a shareholder range analysis provided by the Company to Nasdaq dated March 27, 2026, the Company is not in compliance with Listing Rule 5450(a)(2) (the Minimum Public Holders Rule), which requires the Company to maintain at least 400 total holders for continued listing on The Nasdaq Global Market. The Deficiency Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market. The Deficiency Letter states that the Company has 45 calendar days, or until May 21, 2026, to submit a plan to regain compliance with Listing Rule 5450(a)(2). If Nasdaq accepts the Company's plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Deficiency Letter to evidence compliance with Listing Rule 5450(a)(2). If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the Capital Market). The Company is exploring all options to regain compliance with Listing Rule 5450(a)(2) and intends to submit a plan to regain compliance within the required timeframe. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.
お知らせ • Feb 05Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction.Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction on February 2, 2026. A cash consideration of $1.5 billion will be paid by Primegen Us, Inc. As part of consideration, $1.5 billion is paid towards common equity of DT Cloud Star Acquisition Corporation. The combined company is expected to operate as PrimeGen US. PrimeGen US is anticipated to list on the Nasdaq, subject to Nasdaq approval, under a new ticker symbol. The transaction is subject to subject to antitrust regulations, minimum balance sheet requirements, approval by regulatory board, approval of offer by acquirer shareholders and approval of offer by target shareholders. The transaction is currently expected to close in the second half of 2026. A.G.P. / Alliance Global Partners, LLC acted as financial advisor for Primegen Us, Inc. Sichenzia Ross Ference Carmel LLP acted as legal advisor for Primegen Us, Inc. Loeb & Loeb LLP acted as legal advisor for DT Cloud Star Acquisition Corporation. Steven C. Schinko of Schinko Law acted as legal advisor for Primegen Us, Inc.
お知らせ • Jan 23DT Cloud Star Acquisition Corporation Receives A Deficiency Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn January 15, 2026, DT Cloud Star Acquisition Corporation received a letter (the “Deficiency Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on its Market Value of Listed Securities (“MVLS”) for the period from November 21, 2025 to January 6, 2026, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(b)(2)(A), to maintain a minimum MVLS of $50,0000,000. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until July 14, 2026, in which to regain compliance with Nasdaq continued listing requirement. Nasdaq will provide written confirmation of compliance to the Company and close this matter if the Company’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days during this compliance period. In the event the Company does not regain compliance prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting, in which situation the Company may appeal the delisting determination to a Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the “Capital Market”). The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(b)(2)(A), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.
お知らせ • Nov 29DT Cloud Star Acquisition Corporation Appoints Xunyong Zhou as DirectorOn November 26, 2025, the board of directors of DT Cloud Star Acquisition Corporation (the “Company”) appointed Dr. Xunyong Zhou as a director of the Company. Dr. Zhou, aged 50, is an entrepreneur and researcher with over 6 years of experience in biotechnology and health innovation. Dr. Zhou’s main topic of research is enzyme-based theory for food products, cosmetics, daily chemicals and tea, and he holds over 20 patents as of now. Dr. Zhou is a pioneering figure in biotechnology and digital health innovation. He has served as director for Huakang Biomedical Holdings Company Limited since November 2025. Since January 2023, He has been leading advancements in biological enzyme solutions and cell therapy technologies through Nanjing Hezhen Holding Group Co. Ltd., where he serves as chairman and integrates healthcare generative pre-training transformer and enzyme therapy expertise to co-create a collaborative platform offering next-generation health solutions. Dr. Zhou also oversees Changsha Kerong Health Technology Co. Ltd., which has built a multidisciplinary health service team comprising medical, product, and service experts centered on delivering AI-enhanced health education, health consultation, and health management services. From March 2019 to January 2023, Dr. Zhou took the role of chairman for Zhenzhen Suqian Biotechnology Co. Ltd. Dr. Zhou graduated from Tianjin University of the PRC with a bachelor degree of engineering majoring in business administration in 2002 and Fudan University of the PRC with a master degree of laws in 2011. Dr. Zhou subsequently obtained his doctorate degree in business administration from the Université Nice Sophia Antipolis in Nice, France in 2016. He is currently the honorary chairman of the Vaccine and Immune Health Branch of the Liaoning Immunology Society and a member of the National Enzyme Engineering and Fermentation Engineering Professional Committee.
お知らせ • Sep 12DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025, at 10:00 China Standard Time. Location: offices of loeb & loeb llp, 2206-19, 1 connaught pl, central, Hong Kong
お知らせ • Apr 16Dt Cloud Star Acquisition Corporation Announces Chief Executive Officer Changes, Effective April 14, 2025DT Cloud Star Acquisition Corporation announced that effective April 14, 2025, Bian Fan was removed as Chief Executive Officer of DT Cloud Star Acquisition Corporation by the written consent of the board of directors of the Company. On the same date, to fill the vacancy, the Board appointed Sam Zheng Sun as the Chief Executive Officer of the Company. Mr. Sun was a managing director of the private equity investment department of Affinity Equity Partners, a Hong Kong-headquartered firm that focuses on private equity investments across South Korea, Australia and New Zealand, Greater China and Southeast Asia between March 2021 and February 2023. Prior to that, Mr. Sun was a partner at Sequoia Capital based in Beijing, where he focused on private equity investments, between October 2018 and April 2020. Mr. Sun obtained his MBA degree from UCLA Anderson School of Management in 2007 and Bachelor’s degree in computer science and economics from University of Pittsburgh in 1997.
